Skip to content

13F-HR filed by Commodore Capital LP

Commodore Capital LP filed this 13F-HR for the quarter ended 2022-03-31, filed 2022-05-16, with 27 holding rows worth $447,722,000.

Accession
0001831942-22-000004
Filed
2022-05-16
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2022

A holdings report, 27 entries on the cover page, a total value of $447,722,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $447,722,000 with VALUE read as thousands by filing date, 13F file number 028-20976. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
MERUS N VN5749R100COM1,816,421$48,026,000thousands by filing date
ACLARIS THERAPEUTICS INC COM00461U105Stock2,314,648$39,905,000thousands by filing date
BELLUS HEALTH INC NEW07987C204COM5,637,630$38,787,000thousands by filing date
IVERIC BIO INC46583P102COM2,214,961$37,278,000thousands by filing date
XENON PHARMACEUTICALS INC COM98420N105Stock1,202,613$36,764,000thousands by filing date
CYTOKINETICS INC23282W605COM NEW854,652$31,460,000thousands by filing date
KARYOPHARM THERAPEUTICS INC48576U106COM3,561,052$26,245,000thousands by filing date
COGENT BIOSCIENCES INC19240Q201COM3,500,768$26,221,000thousands by filing date
CYMABAY THERAPEUTICS INC23257D103COM5,738,500$17,847,000thousands by filing date
VIRIDIAN THERAPEUTICS INC92790C104COM951,339$17,590,000thousands by filing date
TRICIDA INC89610F101COM1,744,570$14,340,000thousands by filing date
SATSUMA PHARMACEUTICALS INC80405P107COM3,711,286$14,103,000thousands by filing date
VISTAGEN THERAPEUTICS INC92840H202COM10,097,229$12,521,000thousands by filing date
KURA ONCOLOGY INC COM50127T109Stock776,514$12,486,000thousands by filing date
C4 THERAPEUTICS INC12529R107COM STK481,094$11,671,000thousands by filing date
IMMUNIC INC4525EP101COM893,013$10,091,000thousands by filing date
CELCUITY INC15102K100COM920,464$8,606,000thousands by filing date
CELLDEX THERAPEUTICS INC NEW15117B202COM NEW241,199$8,215,000thousands by filing date
PROTAGONIST THERAPEUTICS74366E102COM331,886$7,859,000thousands by filing date
TENAYA THERAPEUTICS INC87990A106COM513,930$6,054,000thousands by filing date
KALVISTA PHARMACEUTICALS INC483497103COM312,553$4,607,000thousands by filing date
GENOCEA BIOSCIENCES INC372427401COMMON STOCK3,079,756$3,850,000thousands by filing date
INVENTIVA SA46124U107ADS262,658$2,994,000thousands by filing date
DYNE THERAPEUTICS INC COM26818M108Stock305,125$2,941,000thousands by filing date
PMV PHARMACEUTICALS INC69353Y103COM125,000$2,603,000thousands by filing date
BCLS ACQUISITION CORPG0904B105CMN250,000$2,468,000thousands by filing date
MEREO BIOPHARMA GROUP PLC589492107CMN1,954,970$2,190,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001831942-22-000004this filing2022-05-16acceptance time not in the bulk data set